With a staff of 20, Bioclin conducts contract bio-analysis and analytical research and development, with analytical services including liquid chromatography-tandem mass spectrometry (LC/MS/MS).
Its facility holds both good laboratory practice (GLP) and good manufacturing practice (GMP) certification.
Intertek said the purchase "advances its strategic growth in expert support services" to the global pharmaceutical, medical device and drug delivery industry.
Dr John Conti-Ramsden, global director of Intertek's Pharmaceutical Services unit, added that Bioclin "further extends the company's offering in Europe".
Intertek already has laboratory operations in the UK, the US, India and Australia.
Just over a year ago Intertek made a similar acquisition that gave it a new foothold in the lucrative US market.
The firm bought Alta Analytical Laboratories, another supplier of immunochemistry and LC/MS/MS bio-analytical services, to the North American biopharma industry.
Alta had laboratories located in San Diego and near Sacramento, California with around 110 staff.
At the time of the sale, Intertek was already providing testing services to US pharmaceutical clients from its laboratories in the UK, however, the acquisition of Alta "establishes a firm platform for further development for Intertek in the USA", the firm said at the time.
Meanwhile, Intertek said that newly-bought Bioclin will form part of its Pharmaceutical Services group within its Analytical Services division.
Mary Burke, managing director and Dr Brian McKenna, scientific director of Bioclin both said that the joining with Intertek will broaden the company's horizons on a global level, and allows it to provide its services to a wider network of new international clients and markets. Financial terms of the deal were not disclosed.